Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and rates

Objective: Tralokinumab, administered as two 1-mL subcutaneous injections every 2 weeks, at the target dose 300 mg, has been shown to improve lung function in patients with asthma. This study evaluated the pharmacokinetic (PK) and tolerability profile of tralokinumab 300 mg when administered by diff...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Meena, Doughty, Diane, Clawson, Corbin, Li, Xiaobai, White, Nicholas, Agoram, Balaji, van der Merwe, René
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dustri-Verlag Dr. Karl Feistle 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480250/
https://www.ncbi.nlm.nih.gov/pubmed/28590244
http://dx.doi.org/10.5414/CP203023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480250/
https://www.ncbi.nlm.nih.gov/pubmed/28590244
http://dx.doi.org/10.5414/CP203023

Ejemplares similares